Global drugmakers are now navigating a period of acute regulatory uncertainty. The Indian Pharmaceutical Alliance, representing a significant portion of the generic supply chain, warned that punitive tariffs alone are insufficient to trigger a domestic manufacturing revival. The trade group argues that broad structural reforms are required to make U.S. production a viable alternative to existing international hubs.

Sandoz Group, the Swiss generic giant, acknowledged the announcement but remains in a holding pattern. Management stated they would open a dialogue with U.S. policymakers while cautioning that the plan’s scope remains too ill-defined to adjust current investment strategies. Until the White House clarifies the implementation mechanics, the industry faces mounting pressure from both investors and a shifting trade landscape.